Low-dose IL-2 Plus IFN-alpha Immunotherapy as Adjuvant Treatment of Renal Carcinoma.
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy (in terms of event-free survival and overall
survival) of an adjuvant therapy with IFN-alpha plus low-dose of IL2 vs a wait-and-see
program in patient with radically operated renal cell carcinoma.